Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

INTRODUCTION: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. OBJECTIVE: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. DEVELOPMENT: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017. The included studies assessed the drug's efficacy, effectiveness, and safety; screening for infections and vaccination; and administration and monitoring aspects. The initial proposed recommendations were developed by a coordinating group and based on the available evidence and their clinical experience. The consensus process was carried out in 2 stages, with the initial threshold percentage for group agreement established at 80%. The final document with all the recommendations agreed by the working group was submitted for external review and the comments received were considered by the coordinating group. CONCLUSION: The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice.

Implementación y revisión del protocolo para el diagnóstico de la esclerosis múltiple en nuestro hospital / Implementation and evaluation of a protocol of extraction for the diagnosis of multiple sclerosis in our hospital

Objetivo Implementación y evaluación de un protocolo de extracción para el diagnóstico de pacientes con sospecha de esclerosis múltiple (PEM) en el Hospital Universitario Ntra. Sra. de Candelaria y su área de referencia. Resultados De las 270 peticiones de pacientes con sospecha de esclerosis múltiple remitidas antes de la instauración del protocolo PEM, solamente el 31,12% incluían todos los parámetros considerados de utilidad en el diagnóstico, que posteriormente fueron incluidos en el perfil. El restante 68,88% de los estudios quedaron incompletos. En la revisión realizada diez meses después de la instauración de dicho protocolo, se encontró que el 69,23% de las peticiones incluían todos los parámetros del perfil, consiguiéndose invertir los resultados favorablemente. Conclusiones La implementación del protocolo PEM ha supuesto: La unificación de criterios para la correcta solicitud de determinaciones analíticas en pacientes con sospecha de esclerosis múltiple, con el consecuente beneficio para el paciente (estudio completo en una única petición y extracción). La obtención del máximo rendimiento analítico de las muestras. Evitar segundas punciones por petición y/o extracción incompletas. Facilidad y sencillez en la petición y su manejo informático

Objective Implementation and evaluation of a protocol of extraction for the diagnosis of patients with suspicion of multiple sclerosis (MSP) in the University Hospital Ntra. Sra. de Candelaria and its area of reference. Results Out of the 270 requests of patients with suspicion of multiple sclerosis sent before the restoration of protocol MSP, only 31.12% included all the parameters considered useful in the diagnosis, including later in the profile, which implies that the rest ofthe studies, 68.88% were incomplete. In its revision 10 months after the implementation of this protocol, 69.23% of all the requests included all the parameters of the profile, showing the results favorably. Conclusions The implementation of protocol MSP has achieved: The unification of criteria for the correct request of analytical determinations in patients with suspicion of multiple sclerosis and the consequent benefit for the patient (a complete study in only one request and extraction). Obtaining the maximum analytical yield of the samples. To avoid second spinal punctures by incomplete request andlor extraction. Facility and simplicity in the request and its computer science handling